Compare ING Groep NV (ING) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Medpace Holdings Inc — how do they compare? ING Groep NV trades at $33.37 (market cap $93.76B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: ING Groep NV is far larger — about 5.6× Medpace Holdings Inc's market cap, and ING Groep NV pays a 3.95% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Medpace Holdings Inc for 14 Days on average.
| ING | MEDP | |
|---|---|---|
Market Cap | $93.76B | $16.82B |
Volume | 4,620,220 | 223,093 |
Sector | Financials | Health |
52-Week High | $37.27 | $630.19 |
52-Week Low | $23.66 | $393.42 |
Typical Hold Time | 94 Days | 14 Days |
Enterprise Value | $236.48B | $16.44B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.43, down 1.44% today, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with revenue growth and raised 2027 ROE targets above 16%. Valuation metrics show a P/E of 12.86 and P/B of 1.68, while analyst consensus remains strongly positive with 64.7% buy ratings.
ING presents a compelling investment case with solid profitability (28.3% net margin) and consistent earnings outperformance, though negative cash flow trends and regulatory challenges in Australia warrant caution. The stock's current technical weakness may offer entry opportunities for long-term investors attracted by the company's growth trajectory and dividend yield.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
